IP Library Granted Patent US 9,044,382
Granted Patent B2
US 9,044,382 · App. 11/596,649 · Granted Jun 2, 2015

Genetic products differentially expressed in tumors and the use thereof

Inventors: Özlem Türeci (Mainz, DE); Ugur Sahin (Mainz, DE); Michael Koslowski (Mainz, DE); Stefan Fritz (Flonheim, DE); Harald-Gerhard Geppert (Solingen, DE)
Assignee: Ganymed Pharmaceuticals AG
A61K6/00A61K49/00A61K2039/505C07K14/47C07K14/705C07K16/30C12N9/88C12Y406/01002G01N33/57496
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,044,382
App. No.
11/596,649
Granted
Jun 2, 2015
Kind
B2
Abstract

According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.

Claims (7)

1. A method of treating a disease characterized by expression of a tumor-associated antigen that (a) is encoded by a nucleic acid which comprises a nucleic acid sequence of SEQ ID NO: 7 or (b) comprises the amino acid sequence of SEQ ID NO: 16, comprising administering to a patient suffering from said disease an antibody that selectively binds to the tumor-associated antigen, wherein said disease is lung tumor or a pancreatic tumor.

2. The method of claim 1 wherein the disease is a lung tumor.

3. The method according to claim 1 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, a combination of any of the foregoing, and an immunoreactive fragment of any of the foregoing.

4. The method according to claim 1 wherein the antibody is coupled to a therapeutic agent.

5. The method according to claim 4 wherein the therapeutic agent is an anticancer agent, a toxin, a radioactive compound or a cytostatic or cytolytic compound.

6. The method according to claim 1 wherein the binding of the agent causes a cytolytic reaction and/or induces cytokine release.

7. The method of claim 1 wherein the disease is a pancreatic tumor.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2020
From: GANYMED PHARMACEUTICALS GMBH
To: ASTELLAS PHARMA INC
Reel/Frame 052032/0041 →
CHANGE OF NAME Recorded Mar 5, 2020
From: GANYMED PHARMACEUTICALS AG
To: GANYMED PHARMACEUTICALS GMBH
Reel/Frame 052114/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2011
From: TURECI, OZLEM; SAHIN, UGUR; KOSLOWSKI, MICHAEL; FRITZ, STEFAN; GEPPERT, HARALD-GERHARD
To: GANYMED PHARMACEUTICALS AG
Reel/Frame 026974/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2007
From: TURECI, OZLEM; SAHIN, UGUR; KOSLOWSKI, MICHAEL
To: GANYMED PHARMACEUTICALS AG
Reel/Frame 018874/0449 →
Priority Claims (1)
DE 10 2004 024 617 · May 18, 2004 · national
Continuity (1)
Related Publication 20080166350A1 · Jul 10, 2008